Cytokines in Cancer Immunotherapy

Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells

Park, J., Adoro, S., Guinter, T. I., Erman, B., Alag, A., Catálfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835 · see citing works

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608 · see citing works

Interleukin-12 and the regulation of innate resistance and adaptive immunity

Trinchieri, G. (2003) · Nature reviews. Immunology · doi:10.1038/nri1001 · Cited by 3,933 · see citing works

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,803 · see citing works

T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions

Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615 · see citing works

Functional Role of Type I and Type II Interferons in Antiviral Defense

Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453 · see citing works

Interleukin-12: A Proinflammatory Cytokine with Immunoregulatory Functions that Bridge Innate Resistance and Antigen-Specific Adaptive Immunity

Trinchieri, G. (1995) · Annual Review of Immunology · doi:10.1146/annurev.iy.13.040195.001343 · Cited by 2,427 · see citing works

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

Ridge, J. P., Rosa, F. D., & Matzinger, P. (1998) · Nature · doi:10.1038/30989 · Cited by 2,360 · see citing works

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

Bennett, S. R. M., Carbone, F., Karamalis, F., Flavell, R. A., Miller, J. F. A. P., & Heath, W. R. (1998) · Nature · doi:10.1038/30996 · Cited by 2,091 · see citing works

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.7 · Cited by 2,089 · see citing works

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Margolin, K. A., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,043 · see citing works

Jaks and STATs: biological implications.

Leonard, W., & O'Shea, J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.293 · Cited by 1,939 · see citing works

Rapid evolution of a protein in vitro by DNA shuffling

Stemmer, W. P. C. (1994) · Nature · doi:10.1038/370389a0 · Cited by 1,932 · see citing works

Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer

Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C., Caton, J. R., Munshi, N. C., & Crawford, E. D. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003013 · Cited by 1,710 · see citing works

The role of interleukin-2 during homeostasis and activation of the immune system

Boyman, O., & Sprent, J. (2012) · Nature reviews. Immunology · doi:10.1038/nri3156 · Cited by 1,687 · see citing works

Reversible Defects in Natural Killer and Memory Cd8 T Cell Lineages in Interleukin 15–Deficient Mice

Kennedy, M. K., Glaccum, M. B., Brown, S. N., Butz, E. A., Viney, J. L., Embers, M. E., Matsuki, N., Charrier, K., Sedger, L. M., Willis, C. R., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.5.771 · Cited by 1,635 · see citing works

Cytokines in cancer pathogenesis and cancer therapy

Dranoff, G. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1252 · Cited by 1,567 · see citing works

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Louie, A. C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.688 · Cited by 1,387 · see citing works

Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans

Noguchi, M. (1993) · Cell · doi:10.1016/0092-8674(93)90167-o · Cited by 1,338 · see citing works

The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design

Waldmann, T. A. (2006) · Nature reviews. Immunology · doi:10.1038/nri1901 · Cited by 1,174 · see citing works

Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.

Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R. J., Anderson, D. M., Eisenmann, J., Grabstein, K. H., & Caligiuri, M. A. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.4.1395 · Cited by 1,094 · see citing works

New insights into the regulation of T cells by γc family cytokines

Rochman, Y., Spolski, R. J., & Leonard, W. J. (2009) · Nature reviews. Immunology · doi:10.1038/nri2580 · Cited by 1,053 · see citing works

Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients

Rosenberg, S. A., Lotze, M. T., Yang, J. C., Aebersold, P. M., Linehan, W. M., Seipp, C. A., & WHITE, D. E. (1989) · Annals of Surgery · doi:10.1097/00000658-198910000-00008 · Cited by 1,000 · see citing works

Interleukin 15: biology and relevance to human disease

Fehniger, T. A., & Caligiuri, M. A. (2001) · Blood · doi:10.1182/blood.v97.1.14 · Cited by 976 · see citing works

Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes

Boyman, O., Kovář, M., Rubinstein, M., Surh, C., & Sprent, J. (2006) · Science · doi:10.1126/science.1122927 · Cited by 940 · see citing works

JAKs and STATs in immunity, immunodeficiency, and cancer

O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927 · see citing works

IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells

Dubois, S. P., Mariner, J. M., Waldmann, T. A., & Tagaya, Y. (2002) · Immunity · doi:10.1016/s1074-7613(02)00429-6 · Cited by 912 · see citing works

High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

Kirkwood, J. M., Ibrahim, J. G., Sosman, J. A., Sondak, V. K., Agarwala, S. S., Ernstoff, M. S., & Rao, U. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2370 · Cited by 899 · see citing works

Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

Macchi, P., VILLA, A. M., Giliani, S. C., Sacco, M. G., Frattini, A., Porta, F., Ugazio, A. G., Johnston, J. A., Candotti, F., O'Sheai, J. J., et al. (1995) · Nature · doi:10.1038/377065a0 · Cited by 871 · see citing works

Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation

Vincenti, F., Kirkman, R. L., Light, S. E., Bumgardner, G. L., Pescovitz, M. D., Halloran, P. F., Neylan, J. F., Wilkinson, A. H., Ekberg, H., Gaston, R. S., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801153380304 · Cited by 861 · see citing works

Improving the efficacy of antibody-based cancer therapies

Carter, P. M. (2001) · Nature reviews. Cancer · doi:10.1038/35101072 · Cited by 833 · see citing works

Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development

Russell, S. M., Tayebi, N., Nakajima, H., Riedy, M. C., Roberts, J. L., Aman, M. J., Migone, T., Noguchi, M., Markert, M. L., Buckley, R. H., et al. (1995) · Science · doi:10.1126/science.270.5237.797 · Cited by 801 · see citing works

The IL-2/IL-2 receptor system: A current overview

Taniguchi, T. (1993) · Cell · doi:10.1016/0092-8674(93)90152-g · Cited by 775 · see citing works

Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia

Rajala, H. L. M., Eldfors, S., Ellonen, P., van Adrichem, A. J., Kuusanmäki, H. A., Andersson, E. I., Lagström, S., Clemente, M. J., Olson, T. L., Jalkanen, S. E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114885 · Cited by 775 · see citing works

The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response.

Alexander, W., & Hilton, D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.091003.090312 · Cited by 774 · see citing works

Antibody targeted drugs as cancer therapeutics

Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 769 · see citing works

IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation

Liao, W., Lin, J., & Leonard, W. J. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.08.003 · Cited by 744 · see citing works

Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function

Zeng, R., Spolski, R. J., Finkelstein, S. E., Oh, S., Kovanen, P. E., Hinrichs, C. S., Pise-Masison, C. A., Radonovich, M. F., Brady, J. N., Restifo, N. P., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041057 · Cited by 726 · see citing works

Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

Conlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3329 · Cited by 713 · see citing works

Cytokines in Cancer Immunotherapy

Lee, S. Y., & Margolin, K. A. (2011) · Cancers · doi:10.3390/cancers3043856 · Cited by 695 · see citing works

Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity

Spolski, R. J., & Leonard, W. J. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090316 · Cited by 695 · see citing works

Pillars Article: Virus Interference. I. The Interferon. Proc R Soc Lond B Biol Sci. 1957. 147: 258-267

Isaacs, A., & Lindenmann, J.-M. (2015) · The Journal of Immunology · doi:10.1093/jimmunol/195.5.1911 · Cited by 602 · see citing works

The Two Faces of Interferon-γ in Cancer

Zaidi, M. R., & Merlino, G. T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0482 · Cited by 594 · see citing works

Clinical toxicity of interferons in cancer patients: a review.

Quesada, J. R., Talpaz, M., Ríos, A., Kurzrock, R., & Gutterman, J. U. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.2.234 · Cited by 593 · see citing works

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T Cells

Klebanoff, C. A., Finkelstein, S. E., Surman, D. R., Lichtman, M. K., Gattinoni, L., Theoret, M. R., Grewal, N. S., Spiess, P. J., Antony, P. A., Palmer, D. C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307298101 · Cited by 576 · see citing works

Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I

Migone, T.-S., Lin, J.-X., Cereseto, A., Mulloy, J. C., O'Shea, J. J., Franchini, G., & Leonard, W. J. (1995) · Science · doi:10.1126/science.7604283 · Cited by 557 · see citing works

Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’

Levin, A. M., Bates, D. L., Ring, A. M., Krieg, C., Lin, J. T., Su, L., Moraga, I., Raeber, M. E., Bowman, G. R., Novick, P. A., et al. (2012) · Nature · doi:10.1038/nature10975 · Cited by 552 · see citing works

Interleukin-21: a double-edged sword with therapeutic potential

Spolski, R. J., & Leonard, W. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4296 · Cited by 550 · see citing works

Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma

Gutterman, J. U., Blumenschein, G. R., Alexanian, R., Yap, H. Y., Buzdar, A. U., Cabanillas, F., Hortobágyi, G. N., Hersh, E. M., Rasmussen, S. L., Harmon, M. W., et al. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-399 · Cited by 499 · see citing works

Interleukin 12: still a promising candidate for tumor immunotherapy?

Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495 · see citing works

Structure of the Quaternary Complex of Interleukin-2 with Its α, ß, and γ c Receptors

Wang, X., Rickert, M., & García, K. C. (2005) · Science · doi:10.1126/science.1117893 · Cited by 476 · see citing works

Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages

Liao, W., Lin, J.-X., Wang, L., Li, P., & Leonard, W. J. (2011) · Nature Immunology · doi:10.1038/ni.2030 · Cited by 474 · see citing works

The Structure, Function, and Expression of Interleukin-2 Receptors on Normal and Malignant Lymphocytes

Waldmann, T. A. (1986) · Science · doi:10.1126/science.3008337 · Cited by 453 · see citing works

Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma

Crescenzo, R., Abate, F., Lasorsa, E., Tabbò, F., Gaudiano, M., Chiesa, N., Giacomo, F. D., Spaccarotella, E., Barbarossa, L., Ercole, E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.006 · Cited by 445 · see citing works

Contrasting Roles of IL-2 and IL-15 in the Life and Death of Lymphocytes Implications for Immunotherapy

Waldmann, T. A. (2001) · Immunity · doi:10.1016/s1074-7613(09)00091-0 · Cited by 433 · see citing works

IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice

Marks-Kończalik, J., Dubois, S. P., Losi, J. M., Sabzevari, H., Yamada, N., Feigenbaum, L., Waldmann, T. A., & Tagaya, Y. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200363097 · Cited by 433 · see citing works

A potential role for interleukin-15 in the regulation of human natural killer cell survival.

Carson, W. E., Fehniger, T. A., Haldar, S., Eckhert, K., Lindemann, M. J., Lai, C. F., Croce, C. M., Baumann, H., & Caligiuri, M. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119258 · Cited by 419 · see citing works

Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells

Küçük, C., Jiang, B., Hu, X., Zhang, W., Chan, J. K. C., Xiao, W., Lack, N. A., Alkan, C., Williams, J. C., Avery, K. N., et al. (2015) · Nature Communications · doi:10.1038/ncomms7025 · Cited by 394 · see citing works

Meta-Analysis on the Use of Zidovudine and Interferon-Alfa in Adult T-Cell Leukemia/Lymphoma Showing Improved Survival in the Leukemic Subtypes

Bazarbachi, A. A., Plumelle, Y., Ramos, J. C., Tortevoye, P., Otrock, Z. K., Taylor, G. P., Antoine Gessain, A., Harrington, W. J., Panelatti, G., & Hermine, O. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0669 · Cited by 372 · see citing works

Interleukin-15 biology and its therapeutic implications in cancer

Steel, J. C., Waldmann, T. A., & Morris, J. C. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.09.004 · Cited by 361 · see citing works

The interleukin-2 receptor.

Waldmann, T. A. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)49895-x · Cited by 340 · see citing works

GM‐CSF‐based cancer vaccines

Dranoff, G. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18813.x · Cited by 334 · see citing works

Interferons in the treatment of human cancer.

Kirkwood, J. M., & Ernstoff, M. S. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.4.336 · Cited by 333 · see citing works

Interferon Alfa Versus Chemotherapy for Chronic Myeloid Leukemia: A Meta-analysis of Seven Randomized Trials

Chronic Myeloid Leukemia Trialists' Collaborative Group (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.21.1616 · Cited by 323 · see citing works

IL-15Rα chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation

Mortier, E., Woo, T. T., Advincula, R., Gozalo, S., & Ma, A. I. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071913 · Cited by 316 · see citing works

Soluble Interleukin-15 Receptor α (IL-15Rα)-sushi as a Selective and Potent Agonist of IL-15 Action through IL-15Rβ/γ

Mortier, E., Quéméner, A., Vusio, P., Lorenzen, I., Boublik, Y., Grötzinger, J., Plet, A., & Jacques, Y. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508624200 · Cited by 308 · see citing works

Insights into Cytokine–Receptor Interactions from Cytokine Engineering

Spangler, J. B., Moraga, I., Mendoza, J. L., & Garcia, K. C. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120211 · Cited by 304 · see citing works

Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.

Gollob, J., Mier, J. W., Veenstra, K. G., McDermott, D. F., Clancy, D., Clancy, M., & Atkins, M. B. (2000) · PubMed · Cited by 287 · see citing works

Interleukin-2 and interleukin-15: immunotherapy for cancer

Fehniger, T. A., Cooper, M. A., & Caligiuri, M. A. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00021-1 · Cited by 280 · see citing works

Mechanisms of IFN-gamma induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2

Chan, S. H., Kobayashi, M., Santoli, D., PERUSSIA, B., & Trinchieri, G. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.1.92 · Cited by 276 · see citing works

Role of trans-cellular IL-15 presentation in the activation of NK cell–mediated killing, which leads to enhanced tumor immunosurveillance

Kobayashi, H., Dubois, S. P., Sato, N., Sabzevari, H., Sakai, Y., Waldmann, T. A., & Tagaya, Y. (2004) · Blood · doi:10.1182/blood-2003-12-4187 · Cited by 272 · see citing works

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

Caligiuri, M. A., Murray, C., Robertson, M. J., Wang, E. S., Cochran, K., Cameron, C. A., Schow, P. W., Ross, M. E., Klumpp, T. R., & Soiffer, R. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116161 · Cited by 267 · see citing works

Safety and immunologic effects of IL-15 administration in nonhuman primates

Berger, C., Berger, M., Hackman, R. C., Gough, M., Elliott, C., Jensen, M. C., & Riddell, S. R. (2009) · Blood · doi:10.1182/blood-2008-12-189266 · Cited by 244 · see citing works

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial

Windbichler, G. H., Hausmaninger, H., Stummvoll, W., Graf, A. H., Kainz, C., Lahodny, J., Denison, U., Müller‐Holzner, E., & Marth, C. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1053 · Cited by 241 · see citing works

The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy

Waldmann, T. A. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0009 · Cited by 241 · see citing works

Vascular Endothelial Growth Factor Blockade Reduces Intratumoral Regulatory T Cells and Enhances the Efficacy of a GM-CSF–Secreting Cancer Immunotherapy

Li, B., Lalani, A. S., Harding, T. C., Luan, B., Koprivnikar, K. E., Tu, G. H., Prell, R. A., VanRoey, M. J., Simmons, A. D., & Jooss, K. U. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1558 · Cited by 233 · see citing works

High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014

Dutcher, J. P., Schwartzentruber, D. J., Kaufman, H. L., Agarwala, S. S., Tarhini, A. A., Lowder, J. N., & Atkins, M. B. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0026-0 · Cited by 226 · see citing works

In vivo antitumor activity of interleukin 21 mediated by natural killer cells.

Wang, G., Tschoi, M., Spolski, R. J., Lou, Y., Ozaki, K., Feng, C., Kim, G., Leonard, W. J., & Hwu, P. (2003) · PubMed · Cited by 221 · see citing works

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma

Kaufman, H. L., Ruby, C. E., Hughes, T. M., & Slingluff, C. L. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-11 · Cited by 211 · see citing works

Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model

Yu, P., Steel, J. C., Zhang, M., Morris, J. C., & Waldmann, T. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1966 · Cited by 208 · see citing works

Preassociation of IL-15 with IL-15Rα-IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action

Dubois, S. P., Patel, H. J., Zhang, M., Waldmann, T. A., & Müller, J. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2099 · Cited by 206 · see citing works

Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors

Haan, C., Rolvering, C., Raulf, F., Kapp, M., Drückes, P., Thoma, G., Behrmann, I., & Zerwes, H. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.01.012 · Cited by 203 · see citing works

Studies Evaluating the Antitumor Activity and Toxicity of Interleukin-15, a New T Cell Growth Factor: Comparison with Interleukin-2

Munger, W. E., DeJoy, S. Q., Jeyaseelan, R., Torley, L. W., Grabstein, K. H., Eisenmann, J., Paxton, R., Cox, T. C., Wick, M. M., & Kerwar, S. S. (1995) · Cellular Immunology · doi:10.1006/cimm.1995.1216 · Cited by 198 · see citing works

Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation

Soiffer, R. J., Murray, C., Cochran, K., Cameron, C. A., Wang, E. S., Schow, P., Daley, J., & Ritz, J. (1992) · Blood · doi:10.1182/blood.v79.2.517.517 · Cited by 194 · see citing works

Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy.

Tendler, C. L., Greenberg, S. J., Blattner, W. A., Manns, A., Murphy, E. L., Fleisher, T. A., Hanchard, B., Morgan, O., Burton, J. D., & Nelson, D. L. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.13.5218 · Cited by 192 · see citing works

Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques

Waldmann, T. A., Lugli, E., Roederer, M., Perera, L. P., Smedley, J. V., MacAllister, R., Goldman, C. K., Bryant, B. R., Decker, J. M., Fleisher, T. A., et al. (2011) · Blood · doi:10.1182/blood-2010-10-311456 · Cited by 191 · see citing works

The 5′ Untranslated Region, Signal Peptide, and the Coding Sequence of the Carboxyl Terminus of IL-15 Participate in Its Multifaceted Translational Control

Bamford, R. N., DeFilippis, A. P., Azimi, N., Kurys, G., & Waldmann, T. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.9.4418 · Cited by 189 · see citing works

Fas and the art of lymphocyte maintenance.

Lenardo, M. J. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.3.721 · Cited by 187 · see citing works

Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps

Mitra, S., Ring, A. M., Amarnath, S., Spangler, J. B., Li, P., Ju, W., Fischer, S., Oh, J., Spolski, R. J., Weiskopf, K., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.04.018 · Cited by 175 · see citing works

Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy

Waldmann, T. A., & Chen, J. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-110416-120628 · Cited by 173 · see citing works

Transregulation of memory CD8 T-cell proliferation by IL-15Rα+ bone marrow–derived cells

Schluns, K. S., Klonowski, K. D., & Lefrançois, L. (2003) · Blood · doi:10.1182/blood-2003-08-2814 · Cited by 165 · see citing works

IL-21 Activates Both Innate and Adaptive Immunity to Generate Potent Antitumor Responses that Require Perforin but Are Independent of IFN-γ

Ma, H., Whitters, M. J., Konz, R. F., Senices, M., Young, D. A., Grusby, M. J., Collins, M. A., & Dunussi‐Joannopoulos, K. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.2.608 · Cited by 162 · see citing works

Treatment of hairy cell leukemia with recombinant alpha 2 interferon

Ratain, M. J., Golomb, H., Vardiman, J., Vokes, E. E., Rh, J., & Daly, K. (1985) · Blood · doi:10.1182/blood.v65.3.644.bloodjournal653644 · Cited by 161 · see citing works

Interleukin-15 Is an Autocrine/Paracrine Viability Factor for Cutaneous T-Cell Lymphoma Cells

Döbbeling, U., Dummer, R., Laine, E., Potoczna, N., Qin, J., & Burg, G. (1998) · Blood · doi:10.1182/blood.v92.1.252.413k08_252_258 · Cited by 158 · see citing works

Novel Human Interleukin-15 Agonists

Zhu, X., Marcus, W. D., Xu, W. V., Lee, H.-I., Han, K., Egan, J. O., Yovandich, J. L., Rhode, P. R., & Wong, H. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901244 · Cited by 155 · see citing works

Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer

Zhang, M., Yao, Z., Dubois, S. P., Ju, W., Müller, J. R., & Waldmann, T. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902637106 · Cited by 144 · see citing works

High antitumor activity of RLI, an interleukin-15 (IL-15)–IL-15 receptor α fusion protein, in metastatic melanoma and colorectal cancer

Bessard, A., Solé-Jamault, V., Bouchaud, G., Quéméner, A., & Jacques, Y. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0275 · Cited by 138 · see citing works

Development and proliferation of lymphocytes in mice deficient for both interleukins‐2 and ‐4

Sadlack, B., Kühn, R., Schorle, H., Rajewsky, K., Müller, W., & Horak, I. D. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240144 · Cited by 136 · see citing works

Anti-Tac (daclizumab, Zenapax) in the Treatment of Leukemia, Autoimmune Diseases, and in the Prevention of Allograft Rejection: A 25-Year Personal Odyssey

Waldmann, T. A. (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-006-9060-0 · Cited by 132 · see citing works

Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma

Tinhofer, I., Marschitz, I., Henn, T., Egle, A., & Greil, R. (2000) · Blood · doi:10.1182/blood.v95.2.610 · Cited by 130 · see citing works

Targeting IL-15 Receptor-Bearing Cells with an Antagonist Mutant IL-15/Fc Protein Prevents Disease Development and Progression in Murine Collagen-Induced Arthritis

Ferrari‐Lacraz, S., Zanelli, E. H., Neuberg, M., Donskoy, E., Kim, Y. S., Zheng, X. X., Hancock, W. W., Maśliński, W., Li, X. C., Strom, T. B., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.9.5818 · Cited by 130 · see citing works

Preassembly of interleukin 2 (IL-2) receptor subunits on resting Kit 225 K6 T cells and their modulation by IL-2, IL-7, and IL-15: A fluorescence resonance energy transfer study

Damjanovich, S., Bene, L., Matkó, J., Alileche, A., Goldman, C. K., Sharrow, S. O., & Waldmann, T. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13134 · Cited by 128 · see citing works

Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates

Lugli, E., Goldman, C. K., Perera, L. P., Smedley, J. V., Pung, R., Yovandich, J. L., Creekmore, S. P., Waldmann, T. A., & Roederer, M. (2010) · Blood · doi:10.1182/blood-2010-03-275438 · Cited by 125 · see citing works

Janus kinase deregulation in leukemia and lymphoma

Chen, E., Staudt, L. M., & Green, A. R. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.017 · Cited by 123 · see citing works

Interleukin-15 Increases Effector Memory CD8+T Cells and NK Cells in Simian Immunodeficiency Virus-Infected Macaques

Mueller, Y. M., Petrovas, C., Bojczuk, P. M., Dimitriou, I. D., Beer, B., Silvera, P. M., Villinger, F. J., Cairns, J. S., Gracely, E. J., Lewis, M. G., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.8.4877-4885.2005 · Cited by 119 · see citing works

Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model

Yu, P., Steel, J. C., Zhang, M., Morris, J. C., Waitz, R., Fassò, M., Allison, J. P., & Waldmann, T. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203479109 · Cited by 116 · see citing works

Cytokine-secreting tumor cell vaccines

Mach, N., & Dranoff, G. (2000) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00144-8 · Cited by 115 · see citing works

Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling

Pettit, D. K., Bonnert, T. P., Eisenman, J. R., Srinivasan, S., Paxton, R., Beers, C., Lynch, D., Miller, B., Yost, J., Grabstein, K. H., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.4.2312 · Cited by 113 · see citing works

Out-of-Sequence Signal 3 Paralyzes Primary CD4+ T-Cell-Dependent Immunity

Sckisel, G. D., Bouchlaka, M. N., Monjazeb, A. M., Crittenden, M. R., Curti, B. D., Wilkins, D. E. C., Alderson, K. L., Sungur, C. M., Ames, E., Mirsoian, A., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.023 · Cited by 106 · see citing works

Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy

Fehniger, T. A., Bluman, E. M., Porter, M. M., Mrózek, E., Cooper, M. A., VanDeusen, J. B., Frankel, S. R., Stock, W., & Caligiuri, M. A. (2000) · Journal of Clinical Investigation · doi:10.1172/jci6218 · Cited by 106 · see citing works

Characterization and Favorable in Vivo Properties of Heterodimeric Soluble IL-15·IL-15Rα Cytokine Compared to IL-15 Monomer*

Chertova, E. N., Bergamaschi, C., Chertov, O., Sowder, R. C., Bear, J., Roser, J. D., Beach, R. K., Lifson, J. D., Felber, B. K., & Pavlakis, G. N. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.461756 · Cited by 105 · see citing works

The Role of Interferon in Cancer Therapy: A Current Perspective

Goldstein, D., & László, J. (1988) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.38.5.258 · Cited by 105 · see citing works

Role of interferon alpha/beta receptor chain 1 in the structure and transmembrane signaling of the interferon alpha/beta receptor complex.

Constantinescu, S. N., Croze, E., Wang, C., Murti, A., Basu, L., Mullersman, J. E., & Pfeffer, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9602 · Cited by 104 · see citing works

An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response.

Becker, J. C., Varki, N. M., Gillies, S. D., Furukawa, K., & Reisfeld, R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7826 · Cited by 103 · see citing works

IL-15 Mediates Anti-tumor Effects after Cyclophosphamide Injection of Tumor-Bearing Mice and Enhances Adoptive Immunotherapy: The Potential Role of NK Cell Subpopulations

Evans, R., Fuller, J. A., Christianson, G. J., Krupke, D. M., & Troutt, A. B. (1997) · Cellular Immunology · doi:10.1006/cimm.1997.1132 · Cited by 102 · see citing works

Interleukin 21: combination strategies for cancer therapy

Skak, K., Kragh, M., Hausman, D. F., Smyth, M. J., & Sivakumar, P. V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2482 · Cited by 102 · see citing works

IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood

Sneller, M. C., Kopp, W. C., Engelke, K. J., Yovandich, J. L., Creekmore, S. P., Waldmann, T. A., & Lane, H. C. (2011) · Blood · doi:10.1182/blood-2011-09-377804 · Cited by 98 · see citing works

Cancer Immunotherapy by Interleukin-21: Potential Treatment Strategies Evaluated in a Mathematical Model

Cappuccio, A., Elishmereni, M., & Agur, Z. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0241 · Cited by 96 · see citing works

A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer

Steele, N. L., Anthony, A., Saunders, M. P., Esmarck, B., Ehrnrooth, E., Kristjansen, P. E. G., Nihlén, A., Hansen, L. T., & Cassidy, J. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.599 · Cited by 88 · see citing works

Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling

Smith, G. A., Uchida, K., Weiss, A., & Taunton, J. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2056 · Cited by 86 · see citing works

New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-?) treatment of human cancer

Tagliaferri, P., Caraglia, M., Budillon, A., Marra, M., Vitale, G., Viscomi, C., Masciari, S., Tassone, P., Abbruzzese, A., & Venuta, S. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0549-1 · Cited by 85 · see citing works

Antibody–cytokine fusion proteins for the therapy of cancer

Penichet, M. L., & Morrison, S. L. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00345-8 · Cited by 81 · see citing works

Immunomodulatory cytokines as therapeutic agents for melanoma

Nicholas, C., & Lesinski, G. (2011) · Immunotherapy · doi:10.2217/imt.11.45 · Cited by 79 · see citing works

CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP

Ju, W., Zhang, M., Jiang, J.-K., Thomas, C. J., Oh, U., Bryant, B. R., Chen, J., Sato, N., Tagaya, Y., Morris, J. C., et al. (2010) · Blood · doi:10.1182/blood-2010-09-305425 · Cited by 76 · see citing works

An Antagonist IL-15/Fc Protein Prevents Costimulation Blockade-Resistant Rejection

Ferrari‐Lacraz, S., Zheng, X. X., Kim, Y. S., Li, Y., Maśliński, W., Li, X. C., & Strom, T. B. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.6.3478 · Cited by 74 · see citing works

Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia

Waldmann, T. A., Conlon, K. C., Stewart, D. M., Worthy, T., Janik, J. E., Fleisher, T. A., Albert, P. S., Figg, W. D., Spencer, S. D., Raffeld, M. A., et al. (2012) · Blood · doi:10.1182/blood-2012-08-450585 · Cited by 72 · see citing works

NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma

Moga, E., Álvarez, E., Cantó, E., Vidal, S., Rodríguez-Sánchez, J. L., Sierra, J., & Briones, J. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.08.012 · Cited by 71 · see citing works

A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders

Timmerman, J. M., Byrd, J. C., Andorsky, D. J., Yamada, R. E., Kramer, J. M., Muthusamy, N., Hunder, N. N. H., & Pagel, J. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0456 · Cited by 70 · see citing works

Increased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemia

Chen, J., Petrus, M., Bamford, R. N., Shih, J. H., Morris, J. C., Janik, J. E., & Waldmann, T. A. (2011) · Blood · doi:10.1182/blood-2011-04-346759 · Cited by 67 · see citing works

Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma

Berkowitz, J. L., Janik, J. E., Stewart, D. M., Jaffe, E. S., Stetler‐Stevenson, M., Shih, J. H., Fleisher, T. A., Turner, M. L. C., Urquhart, N. E., Wharfe, G., et al. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.09.012 · Cited by 66 · see citing works

Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-β1-mediated growth suppression in adult T-cell leukemia/lymphoma

Nakahata, S., Yamazaki, S., Nakauchi, H., & Morishita, K. (2010) · Oncogene · doi:10.1038/onc.2010.172 · Cited by 66 · see citing works

Failed Adoptive Immunotherapy with Tumor-Specific T Cells

Roychowdhury, S., May, K. F., Tzou, K. S., Lin, T. Y., Bhatt, D., Freud, A. G., Guimond, M., Ferketich, A. K., Liu, Y., & Caligiuri, M. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1860 · Cited by 66 · see citing works

Antibody-Cytokine Fusion Proteins for Treatment of Cancer: Engineering Cytokines for Improved Efficacy and Safety

Young, P. A., Morrison, S. L., & Timmerman, J. M. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.08.002 · Cited by 66 · see citing works

Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism

Chen, J., Petrus, M., Bryant, B. R., Nguyen, V. P., Stamer, M. M., Goldman, C. K., Bamford, R. N., Morris, J. C., Janik, J. E., & Waldmann, T. A. (2008) · Blood · doi:10.1182/blood-2007-09-113654 · Cited by 63 · see citing works

Targeted Cytokines for Cancer Immunotherapy

Lode, H. N., & Reisfeld, R. A. (2000) · Immunologic Research · doi:10.1385/ir:21:2-3:279 · Cited by 61 · see citing works

Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

Bhatia, S., Curti, B. D., Ernstoff, M. S., Gordon, M. S., Heath, E. I., Miller, W. H., Puzanov, I. J., Quinn, D. I., Flaig, T. W., VanVeldhuizen, P. J., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-2 · Cited by 58 · see citing works

GM-CSF-secreting vaccines for solid tumors: moving forward.

Gupta, R., & Emens, L. A. (2010) · PubMed · Cited by 56 · see citing works

IL-15 and IL-2 increase cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR

Roberti, M. P., Barrio, M. M., Bravo, A. I., Rocca, Y. S., Arriaga, J. M., Bianchini, M., Mordoh, J., & Levy, E. M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1360-2 · Cited by 51 · see citing works

Augmented IL-15Rα Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice

Zhang, M., Ju, W., Yao, Z., Yu, P., Wei, B., Simpson, R. J., Waitz, R., Fassò, M., Allison, J. P., & Waldmann, T. A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102604 · Cited by 49 · see citing works

Combination therapy with interleukin-2 and antitumor monoclonal antibodies.

Sondel, P. M., & Hank, J. A. (1997) · PubMed · Cited by 46 · see citing works

Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation

Jin, G.-H., Hirano, T., & Murakami, M. (2008) · International Immunology · doi:10.1093/intimm/dxn036 · Cited by 45 · see citing works

Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)

Leroy, S., Dubois, S. P., Tenaud, I., Chebassier, N., Godard, A., Jacques, Y., & Dréno, B. (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.04192.x · Cited by 40 · see citing works

Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.

(1997) · PubMed · Cited by 40 · see citing works

Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse

Vincent, M., Teppaz, G., Lajoie, L., Solé-Jamault, V., Bessard, A., Maillasson, M., Loisel, S., Béchard, D., Clemenceau, B., Thibault, G., et al. (2014) · mAbs · doi:10.4161/mabs.28699 · Cited by 39 · see citing works

Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.

Soiffer, R. J., Murray, C., Shapiro, C. L., Collins, H., Chartier, S., Lazo, S., & Ritz, J. (1996) · PubMed · Cited by 39 · see citing works

Antibody-interleukin 2 fusion proteins: A new approach to cancer therapy

Reisfeld, R. A., & Gillies, S. D. (1996) · Journal of Clinical Laboratory Analysis · doi:10.1002/(sici)1098-2825(1996)10:3 · Cited by 38 · see citing works

Modest effect of interferon alfa on metastatic renal-cell carcinoma

Amato, R. J. (1999) · The Lancet · doi:10.1016/s0140-6736(05)74876-5 · Cited by 36 · see citing works

Directed evolution of gene-shuffled IFN-α molecules with activity profiles tailored for treatment of chronic viral diseases

Brideau-Andersen, A. D., Huang, X., Sun, S.-C. C., Chen, T. T., Stark, D. M., Sas, I. J., Zadik, L., Dawes, G. N., Guptill, D. R., McCord, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609001104 · Cited by 35 · see citing works

Clinical decisions for chronic myeloid leukemia in the imatinib era

Goldman, J. M., Marin, D., Olavarría, E., & Apperley, J. F. (2003) · Seminars in Hematology · doi:10.1053/shem.2003.50049 · Cited by 33 · see citing works

Interferon response pathways—a paradigm for cytokine signalling?

Müller, M. M., Ibelgaufts, H., & Kerr, I. M. (1994) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.1994.tb00109.x · Cited by 30 · see citing works

IL-21–Driven Neoplasms in SJL Mice Mimic Some Key Features of Human Angioimmunoblastic T-Cell Lymphoma

Jain, S., Chen, J., Nicolae, A., Wang, H., Shin, D., Adkins, E. B., Sproule, T. J., Leeth, C. M., Sakai, T., Kovalchuk, A. L., et al. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.07.021 · Cited by 28 · see citing works

Cytokine treatment in cancer immunotherapy

Ardolino, M., Hsu, J., & Raulet, D. H. (2015) · Oncotarget · doi:10.18632/oncotarget.5095 · Cited by 26 · see citing works

Studies on mechanisms of interferon-gamma action in pancreatic cancer using a data-driven and model-based approach

Lange, F., Rateitschak, K., Fitzner, B., Pöhland, R., Olaf Wolkenhauer, A., & Jaster, R. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-13 · Cited by 26 · see citing works

Targeting the Binding Interface on a Shared Receptor Subunit of a Cytokine Family Enables the Inhibition of Multiple Member Cytokines with Selectable Target Spectrum

Nata, T., Basheer, A., Cocchi, F., Besien, R. F. V., Massoud, R., Jacobson, S., Azimi, N., & Tagaya, Y. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.661074 · Cited by 23 · see citing works

Living with CML: is death no longer the end (point)?

White, D. L., & Hughes, T. P. (2015) · Blood · doi:10.1182/blood-2015-05-644732 · Cited by 7 · see citing works

Tighter ties that bind

Boder, E. T. (2012) · Nature · doi:10.1038/484463a · Cited by 4 · see citing works

MUTATIONS OF Jak-3 GENE IN PATIENTS WITH AUTOSOMAL SEVERE COMBINED IMMUNE DEFICIENCY (SCID)

Liu, A. (1996) · PEDIATRICS · doi:10.1542/peds.98.2.350b · Cited by 3 · see citing works

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

Zhang, Y., & Zhang, Z. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,815 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

Cytokines in clinical cancer immunotherapy

Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberría, I., Aznar, M. A., Perez‐Gracia, J. L., Rodriguez-Ruiz, M. E., Ponz‐Sarvisé, M., Álvarez, E. C., & Melero, I. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,190 · see citing works

Targeting Tumor Microenvironment for Cancer Therapy

Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040840 · Cited by 1,187 · see citing works

Harnessing cytokines and chemokines for cancer therapy

PROPPER, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 1,005 · see citing works

Interleukins in cancer: from biology to therapy

Briukhovetska, D., Dörr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00363-z · Cited by 791 · see citing works

Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency

Li, Z., Lai, X., Fu, S., Ren, L. F., Cai, H., Zhang, H., Gu, Z., Ma, X., & Luo, K. (2022) · Advanced Science · doi:10.1002/advs.202201734 · Cited by 688 · see citing works

Targeting cytokine and chemokine signaling pathways for cancer therapy

Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 491 · see citing works

Emerging new therapeutic antibody derivatives for cancer treatment

Jin, S., Sun, Y., Xiao, L., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 461 · see citing works

Recent advances in nanomaterial-based synergistic combination cancer immunotherapy

Sang, W., Zhang, Z., Dai, Y., & Chen, X. S. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00896e · Cited by 408 · see citing works

Immunologic tumor microenvironment modulators for turning cold tumors hot

Khosravi, G. R., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · 癌症：英文版 · doi:10.1002/cac2.12539 · Cited by 384 · see citing works

The γc Family of Cytokines: Basic Biology to Therapeutic Ramifications

Leonard, W. J., Lin, J., & O’Shea, J. J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.028 · Cited by 378 · see citing works

IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy

Zhou, T., Damsky, W., Weizman, O.-E., McGeary, M. K., Hartmann, K. P., Rosen, C. E., Fischer, S., Jackson, R. P., Flavell, R. A., Wang, J., et al. (2020) · Nature · doi:10.1038/s41586-020-2422-6 · Cited by 364 · see citing works

Engineering strategies to enhance oncolytic viruses in cancer immunotherapy

Tian, Y., Xie, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00951-x · Cited by 305 · see citing works

Platelets, Thrombo-Inflammation, and Cancer: Collaborating With the Enemy

Palacios-Acedo, A.-L., Mège, D., Crescence, L., Dignat‐George, F., Dubois, C., & Panicot‐Dubois, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01805 · Cited by 277 · see citing works

Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy

Liu, J.-Q., Zhang, C., Zhang, X., Yan, J., Zeng, C., Talebian, F., Lynch, K., Zhao, W., Hou, X., Du, S., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.021 · Cited by 267 · see citing works

Neuroinflammation, Sleep, and Circadian Rhythms

Zielinski, M. R., & Gibbons, A. J. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.853096 · Cited by 263 · see citing works

First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia

Cooley, S., He, F. C., Bachanová, V., Vercellotti, G. M., DeFor, T. E., Curtsinger, J., Robertson, P., Grzywacz, B. J., Conlon, K. C., Waldmann, T. A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028332 · Cited by 238 · see citing works

Wnt signaling pathway in cancer immunotherapy

Zhou, Y., Jiang, X., Luo, H., Meng, X., Chen, M., & Zhu, D. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.034 · Cited by 238 · see citing works

The role of cytokines in T‐cell memory in health and disease

Raeber, M. E., Zurbuchen, Y., Impellizzieri, D., & Boyman, O. (2018) · Immunological Reviews · doi:10.1111/imr.12644 · Cited by 226 · see citing works

Revisiting Immunotherapy: A Focus on Prostate Cancer

Cha, H.-R., Lee, J. H., & Ponnazhagan, S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2948 · Cited by 225 · see citing works

Biological drug and drug delivery-mediated immunotherapy

Xiao, Q., Li, X., Li, Y., Wu, Z., Xu, C., Chen, Z., & He, W. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.12.018 · Cited by 220 · see citing works

Killers 2.0: NK cell therapies at the forefront of cancer control

Hodgins, J. J., Khan, S., Park, M. M., Auer, R. C., & Ardolino, M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129338 · Cited by 213 · see citing works

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

Wang, H., Kaur, G., Sankin, A. I., Chen, F., Guan, F., & Zang, X. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0746-1 · Cited by 204 · see citing works

Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy

Liu, Z., Zhou, Z., Dang, Q., Xu, H. M., Lv, J., Li, H., & Han, X. (2022) · Theranostics · doi:10.7150/thno.76854 · Cited by 198 · see citing works

Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy

Yang, Y., & Lundqvist, A. (2020) · Cancers · doi:10.3390/cancers12123586 · Cited by 190 · see citing works

Introduction to the Immune System

McComb, S., Thiriot, A., Akache, B., Krishnan, L., & Stark, F. C. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9597-4_1 · Cited by 186 · see citing works

Gene modification strategies for next-generation CAR T cells against solid cancers

Tian, Y., Li, Y., Shao, Y., & Zhang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00890-6 · Cited by 177 · see citing works

Technological advances in cancer immunity: from immunogenomics to single‐cell analysis and artificial intelligence

Xu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00729-7 · Cited by 163 · see citing works

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects

Liu, Z., Liu, X., Liang, J., Liu, Y., Hou, X., Zhang, M., Li, Y., & Jiang, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.765101 · Cited by 151 · see citing works

The JAK-STAT pathway: from structural biology to cytokine engineering

Lv, Y., Qi, J., Babon, J. J., Cao, L., Fan, G.-H., Lang, J., Zhang, J., Mi, P., Kobe, B., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01934-w · Cited by 149 · see citing works

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer

Luo, C., Wang, P., He, S., Zhu, J., Shi, Y., & Wang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.919072 · Cited by 147 · see citing works

The Promise of Combining Radiation Therapy With Immunotherapy

Jagodinsky, J. C., Harari, P. M., & Morris, Z. S. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.04.023 · Cited by 144 · see citing works

Immunotherapy for hepatocellular carcinoma: Current status and future perspectives

Mandlik, D. S., Mandlik, S. K., & Choudhary, H. B. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.1054 · Cited by 144 · see citing works

Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity

Kobayashi, H., Furusawa, A., Rosenberg, A., & Choyke, P. L. (2020) · International Immunology · doi:10.1093/intimm/dxaa037 · Cited by 143 · see citing works

Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo–immunotherapy

Jiang, M., Zeng, J., Zhao, L., Zhang, M., Ma, J., Guan, X., & Zhang, W. (2021) · Nanoscale · doi:10.1039/d1nr05512g · Cited by 140 · see citing works

IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion

Conlon, K. C., Potter, E. L., Pittaluga, S., Lee, C. R., Miljković, M. D., Fleisher, T. A., Dubois, S. P., Bryant, B. R., Petrus, M. N., Perera, L. P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3468 · Cited by 136 · see citing works

Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance

Shi, L., Sheng, J., Chen, G., Zhu, P., Shi, C., Li, B., Park, C., Wang, J., Zhang, B., Liu, Z., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000973 · Cited by 132 · see citing works

Small extracellular vesicles in cancer

Abhange, K. K., Makler, A., Wen, Y., Ramnauth, N., Mao, W., Asghar, W., & Wan, Y. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.03.015 · Cited by 130 · see citing works

Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer

Waldmann, T. A., Miljković, M. D., & Conlon, K. C. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20191062 · Cited by 129 · see citing works

Recent Advances in Molecular Mechanisms of Cancer Immunotherapy

Kciuk, M., Yahya, E. B., Mohamed, M. M. I., Rashid, S., Iqbal, M. O., Kontek, R., Abdulsamad, M. A., & Allaq, A. A. (2023) · Cancers · doi:10.3390/cancers15102721 · Cited by 128 · see citing works

Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy

Chen, Y., Shi, S., & Dai, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113903 · Cited by 123 · see citing works

Targeting inflammation as cancer therapy

Wang, M., Chen, S., He, X., Yuan, Y., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01528-7 · Cited by 122 · see citing works

Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy

Carlson, R. D., Flickinger, J. C., & Snook, A. E. (2020) · Toxins · doi:10.3390/toxins12040241 · Cited by 118 · see citing works

Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial

Shenderov, E., Marzo, A. M. D., Lotan, T. L., Wang, H., Chan, S., Lim, S. J., Ji, H., Allaf, M. E., Chapman, C. G., Moore, P. A., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02284-w · Cited by 116 · see citing works

Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy

Knudson, K. M., Hicks, K. C., Alter, S., Schlom, J., & Gameiro, S. R. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0551-y · Cited by 114 · see citing works

Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication

Wang, H., Wang, T., Yan, S., Tang, J., Zhang, Y., Wang, L., Xu, H., & Tu, C. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02183-9 · Cited by 113 · see citing works

Exploring dendrimer-based drug delivery systems and their potential applications in cancer immunotherapy

Mukherjee, S., Mukherjee, S., Abourehab, M. A. S., Sahebkar, A., & Kesharwani, P. (2022) · European Polymer Journal · doi:10.1016/j.eurpolymj.2022.111471 · Cited by 111 · see citing works

Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy

Chulpanova, D. S., Kitaeva, K. V., Green, A. R., Rizvanov, A. A., & Solovyeva, V. V. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00402 · Cited by 109 · see citing works

Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges

Wang, M., Yu, F., & Zhang, Y. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02214-5 · Cited by 105 · see citing works

Bystander T Cells: A Balancing Act of Friends and Foes

Whiteside, S. K., Snook, J. P., Williams, M. A., & Weis, J. J. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.10.003 · Cited by 103 · see citing works

Immunotherapy: an alternative promising therapeutic approach against cancers

Gupta, S. L., Basu, S., Soni, V., & Jaiswal, R. K. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07525-8 · Cited by 102 · see citing works

Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology

Bockamp, E., Rosigkeit, S., Siegl, D., & Schuppan, D. (2020) · Cells · doi:10.3390/cells9092102 · Cited by 94 · see citing works

The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy

Yu, Y. (2023) · Cancers · doi:10.3390/cancers15082323 · Cited by 92 · see citing works

Engineered Bio‐Based Hydrogels for Cancer Immunotherapy

Peng, Y., Liang, S., Meng, Q., Liu, D., Ma, K., Zhou, M., Yun, K., Rao, L., & Wang, Z. (2024) · Advanced Materials · doi:10.1002/adma.202313188 · Cited by 91 · see citing works

Human Cancer and Platelet Interaction, a Potential Therapeutic Target

Wang, S., Li, Z., & Xu, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041246 · Cited by 88 · see citing works

Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways

Afshari, A. R., Sanati, M., Mollazadeh, H., Kesharwani, P., Johnston, T. P., & Sahebkar, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.01.008 · Cited by 87 · see citing works

Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade

Jagodinsky, J. C., Vera, J. M., Jin, W. J., Shea, A. G., Clark, P. A., Sriramaneni, R. N., Havighurst, T. C., Chakravarthy, I., Allawi, R. H., Kim, K., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk0642 · Cited by 87 · see citing works

Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery

Chen, A. X. Y., Yap, K. M., Kim, J. S., Sek, K., Huang, Y., Dunbar, P. A., Wiebking, V., Armitage, J. D., Munoz, I., Todd, K. L., et al. (2025) · Nature · doi:10.1038/s41586-025-09212-7 · Cited by 85 · see citing works

Control of memory CD8+ T cell longevity and effector functions by IL-15

Nolz, J. C., & Richer, M. J. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.11.011 · Cited by 84 · see citing works

Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction

Ramos, M. I. P., Tian, L., de Ruiter, E. J., Song, C. H., Paucarmayta, A., Singh, A., Elshof, E., Vijver, S. V., Shaik, J. S., Bosiacki, J., et al. (2021) · eLife · doi:10.7554/elife.62927 · Cited by 84 · see citing works

A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy

Quijano‐Rubio, A., Bhuiyan, A. M., Yang, H., Leung, I., Bello, E., Ali, L. R., Zhangxu, K., Perkins, J., Chun, J.-H., Wang, W., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01510-z · Cited by 82 · see citing works

Hyaluronidase: structure, mechanism of action, diseases and therapeutic targets

Lu, J., Zhao, Z., Pan, L., Wu, H. C., Wang, S., Tong, X., & Wu, S. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00299-y · Cited by 82 · see citing works

Next-generation cytokines for cancer immunotherapy

Xue, D., Hsu, E. J., Fu, Y., & Peng, H. (2021) · Antibody Therapeutics · doi:10.1093/abt/tbab014 · Cited by 81 · see citing works

Immunotherapy

Sahu, M., & Suryawanshi, H. (2021) · Journal of Oral and Maxillofacial Pathology · doi:10.4103/0973-029x.325257 · Cited by 81 · see citing works

Research progress of interleukin-15 in cancer immunotherapy

Cai, M., Huang, X., Huang, X., Ju, D., Zhu, Y. Z., & Li, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1184703 · Cited by 81 · see citing works

The In Vitro Immunomodulatory Effects Of Gold Nanoparticles Synthesized From Hypoxis hemerocallidea Aqueous Extract And Hypoxoside On Macrophage And Natural Killer Cells

Elbagory, A. M., Hussein, A. A., & Meyer, M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s216972 · Cited by 80 · see citing works

Non-coding RNAs shuttled via exosomes reshape the hypoxic tumor microenvironment

Wang, W., Han, Y., Jo, H. A., Lee, J., & Song, Y. S. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00893-3 · Cited by 80 · see citing works

Tissue-resident immune cells: from defining characteristics to roles in diseases

Li, J., Chu, X., Li, C., & He, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02050-5 · Cited by 80 · see citing works

Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity

Shen, S., Sckisel, G. D., Sahoo, A., Lalani, A., Otter, D. D., Pearson, J. T., DeVoss, J., Cheng, J., Casey, S. C., Case, R. B., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00832 · Cited by 79 · see citing works

Histamine in cancer immunology and immunotherapy. Current status and new perspectives

Sarasola, M. D. L. P., Delgado, M. A. T., Nicoud, M. B., & Medina, V. A. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.778 · Cited by 78 · see citing works

Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors

Nash, A., Jarvis, M., Aghlara-Fotovat, S., Mukherjee, S., Hernández, A., Hecht, A. D., Rios, P., Ghani, S., Joshi, I., Isa, D., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm1032 · Cited by 78 · see citing works

Immune Tumor Microenvironment in Ovarian Cancer Ascites

Almeida-Nunes, D. L., Mendes‐Frias, A., Silvestre, R., Dinis‐Oliveira, R. J., & Ricardo, S. A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810692 · Cited by 78 · see citing works

Engineering cytokines for cancer immunotherapy: a systematic review

Fu, Y., Tang, R., & Zhao, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1218082 · Cited by 78 · see citing works

Computational immunogenomic approaches to predict response to cancer immunotherapies

Addala, V., Newell, F., Pearson, J. V., Redwood, A., Robinson, B. W. S., Creaney, J., & Waddell, N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00830-6 · Cited by 77 · see citing works

Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma

Qin, Y., Zheng, X., Gao, W., Wang, B., & Wu, Y. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.01.011 · Cited by 75 · see citing works

Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy

Gaggero, S., Witt, K., Carlsten, M., & Mitra, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.621225 · Cited by 75 · see citing works

Nanotechnologies for the delivery of biologicals: Historical perspective and current landscape

Durán‐Lobato, M., López-Estévez, A. M., Cordeiro, A. S., Dacoba, T. G., Crecente‐Campo, J., Torres, D., & Alonso, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113899 · Cited by 71 · see citing works

Human intratumoral therapy: Linking drug properties and tumor transport of drugs in clinical trials

Huang, A., Pressnall, M. M., Lu, R., Huayamares, S. G., Griffin, J. D., Groer, C. E., DeKosky, B. J., Forrest, M. L., & Berkland, C. J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.029 · Cited by 69 · see citing works

Targeted Microbubbles for Drug, Gene, and Cell Delivery in Therapy and Immunotherapy

Navarro-Becerra, J. Á., & Borden, M. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061625 · Cited by 69 · see citing works

Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives

Atallah‐Yunes, S. A., & Robertson, M. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.872010 · Cited by 68 · see citing works

Investigating the Dynamic Interplay Between Cellular Immunity and Tumor Cells in the Fight Against Cancer: An Updated Comprehensive Review

Aghapour, S. A., Torabizadeh, M., Bahreiny, S. S., Saki, N., Far, M. A. J., Avarvand, A. Y., Ghasemi, K. D. M., Aghaei, M., Abolhasani, M. M., Sharifani, M. S., et al. (2024) · Iranian Journal of Blood and Cancer · doi:10.61186/ijbc.16.2.84 · Cited by 68 · see citing works

Non-pathogenic E. coli displaying decoy-resistant IL18 mutein boosts anti-tumor and CAR NK cell responses

Yang, S., Sheffer, M., Kaplan, I. E., Wang, Z., Tarannum, M., Dinh, K., Abdulhamid, Y., Bobilev, E., Shapiro, R., Porter, R., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02418-6 · Cited by 66 · see citing works

Biomaterials to enhance adoptive cell therapy

Eckman, N., Nejatfard, A., Cavet, R., Grosskopf, A. K., & Appel, E. A. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00148-z · Cited by 65 · see citing works

Advances and prospects of RNA delivery nanoplatforms for cancer therapy

Attia, M. S., Kijanka, G. S., Nguyen, N., Zhang, J., & An, H. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.09.009 · Cited by 64 · see citing works

Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression

Nirschl, C. J., Brodkin, H. R., Hicklin, D. J., Ismail, N., Morris, K., Seidel‐Dugan, C., Steiner, P., Steuert, Z., Sullivan, J. M., Tyagi, E., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0831 · Cited by 63 · see citing works

Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy

Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 63 · see citing works

Freeze-drying for the preservation of immunoengineering products

Kommineni, N., Butreddy, A., Jyothi, V. G. S. S., & Angsantikul, P. (2022) · iScience · doi:10.1016/j.isci.2022.105127 · Cited by 62 · see citing works

Cytokines as potential combination agents with PD‐1/PD‐L1 blockade for cancer treatment

Mohammad, G. R. K. S., Ghahremanloo, A., Soltani, A., Fathi, E., & Hashemy, S. I. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29491 · Cited by 60 · see citing works

Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy

Tarannum, M., Romee, R., & Shapiro, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859177 · Cited by 59 · see citing works

Multifunctional nanocomposites modulating the tumor microenvironment for enhanced cancer immunotherapy

Sharma, P., & Otto, M. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.08.022 · Cited by 59 · see citing works

Exosomes are the Driving Force in Preparing the Soil for the Metastatic Seeds: Lessons from the Prostate Cancer

Saber, S. H., Ali, H. E. A., Gaballa, R., Gaballah, M. S. A., Ali, H. I., Zerfaoui, M., & Elmageed, Z. Y. A. (2020) · Cells · doi:10.3390/cells9030564 · Cited by 59 · see citing works

Immunological nanomaterials to combat cancer metastasis

Pan, Y., Cheng, J., Zhu, Y., Zhang, J., Fan, W., & Chen, X. S. (2024) · Chemical Society Reviews · doi:10.1039/d2cs00968d · Cited by 58 · see citing works

NIR‐II Light Powered Asymmetric Hydrogel Nanomotors for Enhanced Immunochemotherapy

Wang, Y., Chen, W., Wang, Z., Zhu, Y., Zhao, H., Wu, K., Wu, J., Zhang, W., Zhang, Q., Guo, H., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202212866 · Cited by 57 · see citing works

Macrophage-derived cytokines in pneumonia: Linking cellular immunology and genetics

Dukhinova, M., Kokinos, E. K., Kuchur, P. D., Komissarov, A., & Штро, А. А. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.11.003 · Cited by 56 · see citing works

Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what?

Zuo, S., Song, J., Zhang, J., He, Z., Sun, B., & Sun, J. (2021) · Theranostics · doi:10.7150/thno.59953 · Cited by 56 · see citing works

Recent advances in immunotherapy for hepatocellular carcinoma

Khan, A. A., Liu, Z., & Xu, X. (2021) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2021.06.010 · Cited by 56 · see citing works

Car T Cells in Solid Tumors: Overcoming Obstacles

Rojas, J., Diaz, M. P., Palmar, J., Galán‐Freyle, N. J., Morillo, V., Escalona, D., González-Torres, H. J., Torres, W., Quiroz, E. N., Rivera-Porras, D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084170 · Cited by 56 · see citing works

Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives

Bagherifar, R., Kiaie, S. H., Hatami, Z., Ahmadi, A., Sadeghnejad, A., Baradaran, B., Jafari, R., & Javadzadeh, Y. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00861-0 · Cited by 55 · see citing works

Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal

Wang, Z., Chen, L., Ma, Y., Li, X., Hu, A., Wang, W., Wang, W., Li, X., Tian, B., & Dong, J. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00975-5 · Cited by 55 · see citing works

Cytokines in the Treatment of Cancer

Conlon, K. C., Miljković, M. D., & Waldmann, T. A. (2018) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0019 · Cited by 523 · see citing works

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

Floros, T., & Tarhini, A. A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.015 · Cited by 229 · see citing works

Cytokines in clinical cancer immunotherapy

Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberría, I., Aznar, M. A., Perez‐Gracia, J. L., Rodriguez-Ruiz, M. E., Ponz‐Sarvisé, M., Álvarez, E. C., & Melero, I. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,190 · see citing works

Cytokine therapies

Ribatti, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21798-2.00008-7

Cytokines in cancer therapy

Parkinson, D. R. (1989) · Urology · doi:10.1016/0090-4295(89)90237-9 · Cited by 34 · see citing works